Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
Abstract
Data di Pubblicazione:
2014
Abstract:
We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART.
Tipologia CRIS:
1.5 Abstract in rivista
Elenco autori:
Fabbiani, Massimiliano; Di Giambenedetto, Simona; QUIROS ROLDAN, Maria Eugenia; Latini, Alessandra; Vullo, Vincenzo; Antinori, Andrea; Castagna, Antonella; Orofino, Giancarlo; Francisci, Daniela; Grilli, Elisabetta; Madeddu, Giordanu; Grima, Pierfrancesco; Rusconi, Stefano; Del Pin, Barbara; Mondi, Annalisa; Borghetti, Alberto; Foca', Emanuele; Colafigli, Manuela; De Luca, Andrea; Cauda, Roberto
Link alla scheda completa:
Pubblicato in: